{"response": {"meta": {"time": 170, "hits": 2, "offset": 0}, "docs": [{"news_desk": "Money and Business/Financial Desk", "document_type": "article", "_id": "4fd2216f8eb7c8105d7a5ed8", "headline": {"main": "The Race to Cash In On the Genetic Code"}, "pub_date": "1999-08-29T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By LAWRENCE M. FISHER", "person": [{"rank": 1, "organization": "", "role": "reported"}]}, "abstract": "Article on human genome industry, which hopes to cash in on new wave of medical therapies expected when entire human genetic code is untangled and identified; leading companies, Millennium Pharmaceuticals of Cambridge, Mass, and Human Genome Sciences of Rockville, Md, aim to develop drugs while Incyte Pharmaceuticals of Palo Alta, Calif, and Celera Genomics Group of Rockville, are focusing on selling data about genes; drawings; photos (L)", "web_url": "http://www.nytimes.com/1999/08/29/business/the-race-to-cash-in-on-the-genetic-code.html", "section_name": "Health; Business", "lead_paragraph": "BEFORE there was an Internet bubble, before biotechnology left a bad taste in money managers' mouths, capital was ventured and shares were sold in a group of companies that aimed to leapfrog the Government's multibillion-dollar effort to map the human genome. By sequencing and patenting genes ahead of the publicly financed laboratories, the investors thought, these companies would control the next era of health care -- and make their founders and shareholders rich. But now, as the international race to spell out the precise sequence of the three billion letters in the human genetic code sprints to the finish line, the markets are demanding that the gene merchants deliver the goods. Investors are starting to demand not just science, but a viable business model, too.", "snippet": "BEFORE there was an Internet bubble, before biotechnology left a bad taste in money managers' mouths, capital was ventured and shares were sold in a group of companies that aimed to leapfrog the Government's multibillion-dollar effort to map the...", "blog": [], "keywords": [{"value": "INCYTE PHARMACEUTICALS INC", "name": "organizations"}, {"value": "CELERA GENOMICS GROUP", "name": "organizations"}, {"value": "HUMAN GENOME SCIENCES INC", "name": "organizations"}, {"value": "MILLENNIUM PHARMACEUTICALS INC", "name": "organizations"}, {"value": "GENETICS AND HEREDITY", "name": "subject"}, {"value": "DRUGS (PHARMACEUTICALS)", "name": "subject"}, {"value": "INDUSTRY PROFILES", "name": "subject"}], "print_page": "1", "type_of_material": "News", "word_count": 3329, "subsection_name": null, "multimedia": []}, {"news_desk": "Book Review Desk", "document_type": "article", "_id": "4fd201698eb7c8105d765776", "headline": {"main": "The Middling of the American Brow"}, "pub_date": "1999-08-29T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By Thomas Hine", "person": [{"lastname": "Hine", "rank": 1, "firstname": "Thomas", "organization": "", "role": "reported"}]}, "abstract": "Thomas Hine reviews books American Culture, American Tastes: Social Change and the 20th Century by Michael Kammen and Consuming Desires, edited by Roger Rosenblatt; drawing (M)", "web_url": "http://www.nytimes.com/1999/08/29/books/the-middling-of-the-american-brow.html", "section_name": "Arts; Books", "lead_paragraph": "AMERICAN CULTURE, AMERICAN TASTES Social Change and the 20th Century. By Michael Kammen. Illustrated. 320 pp. New York: Alfred A. Knopf. $30.", "snippet": "AMERICAN CULTURE, AMERICAN TASTES  Social Change and the 20th Century.  By Michael Kammen.  Illustrated. 320 pp. New York: Alfred A. Knopf. $30.", "blog": [], "keywords": [{"value": "AMERICAN CULTURE, AMERICAN TASTES (BOOK)", "name": "creative_works"}, {"value": "CONSUMING DESIRES (BOOK)", "name": "creative_works"}, {"value": "ROSENBLATT, ROGER", "name": "persons"}, {"value": "KAMMEN, MICHAEL", "name": "persons"}, {"value": "REVIEWS", "name": "subject"}, {"value": "BOOKS AND LITERATURE", "name": "subject"}], "print_page": "13", "type_of_material": "Review", "word_count": 1421, "subsection_name": null, "multimedia": []}]}, "status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}